单位:[a]Liver Research Center, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[b]Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China医技科室北京市临床医学研究所实验中心首都医科大学附属北京友谊医院[c]National Clinical Research Center of Digestive Diseases, Beijing, China首都医科大学附属北京友谊医院
Mature crosslinked-poly-elastin deposition has been found to be associated with liver fibrosis. However, the regulation of crosslinked/insoluble elastin in liver fibrosis remains largely unknown. Here, we investigated the contribution of lysyl oxidases (LOXs) family, mediated elastin crosslinking, to liver fibrogenesis. We established carbon tetrachloride (CCl4)-induced liver fibrotic and cirrhotic models and found that crosslinked/insoluble elastin levels spiked only in cirrhosis stage during disease progression, in comparison to collagen I levels which increased continuously though all stages. Among the LOXs family members, only LOX-like 1 (LOXL1) levels were coincident with the appearance of crosslinked/insoluble elastin. These coincidences included that LOXL1 expression increased (34 fold) in cirrhosis, localized with a-smooth muscle actin (SMA) and was absent in normal and fibrotic livers. In LX-2 cells, LOXL1 silencing arrested expression of alpha-SMA, elastin and collagen I. Our previously characterized adeno-associated vector (AAV) 2/8 shRNA was shown to effectively down regulate LOXL1 expression in CCl4 induced fibrosis mice models. These resulted in delicate and thinner septa and less crosslinked elastin, with a 58% loss of elastin area and 51% decrease of collagen area. Our findings strongly suggested that elastin crosslinking and LOXL1 were co-associated with liver cirrhosis, while selective inhibition of LOXL1 arrested disease progression by reducing crosslinking of elastin.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670539, 81500456]; Chinese Foundation for Hepatitis Prevention and Control of the WBN Research Foundation [CFHPC20151009]
第一作者单位:[a]Liver Research Center, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing, China[c]National Clinical Research Center of Digestive Diseases, Beijing, China
通讯作者:
通讯机构:[a]Liver Research Center, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing, China[c]National Clinical Research Center of Digestive Diseases, Beijing, China[*1]Liver Research Center, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University. National Clinical Research Center of Digestive Diseases, No. 95 Yong An Road, Xi Cheng District, Beijing 100050, China.
推荐引用方式(GB/T 7714):
Wenshan Zhao,Aiting Yang,Wei Chen,et al.Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking[J].BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS of DISEASE.2018,1864(4):1129-1137.doi:10.1016/j.bbadis.2018.01.019.
APA:
Wenshan Zhao,Aiting Yang,Wei Chen,Ping Wang,Tianhui Liu...&Hong You.(2018).Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS of DISEASE,1864,(4)
MLA:
Wenshan Zhao,et al."Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking".BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS of DISEASE 1864..4(2018):1129-1137